Effect of Glucocorticoid on Exogenous Insulin Antibody Syndrome
Status:
Not yet recruiting
Trial end date:
2023-05-20
Target enrollment:
Participant gender:
Summary
Diabetic patients who have long-term insulin used can product antibody against exogenous
insulin, the investigators named this condition Exogenous insulin antibody syndrome (EIAs).
Exogenous insulin antibody can cause blood glucose fluctuation, high blood glucose and
refractory hypoglycemia, and have a serious impact on the health of diabetic patients. After
adding glucocorticoid, some EIAs patients can reduce insulin dosage, correct hypoglycemia,
even eliminate insulin antibody in about half a year, and achieve the goal of blood glucose
stability. But up to now, there is no study to evaluate the improvement of blood glucose by
glucocorticoid intervention in EIAS patients receiving insulin therapy. This project plans to
collect 20 cases of EIAS and carry out a randomized, double-blind, placebo-controlled
clinical trial to evaluate the improvement of blood glucose by glucocorticoid intervention.